Vetter is expanding capacities in Germany and the USA

Vetter, as a family business, relies on independence and long-term planning, and is planning to expand its production capacity at the Ravensburg and Langenargen sites in addition to ongoing investment projects. © Vetter Pharma International GmbH

Vetter Advisory Board Decides on Strategic Investments for Continued Independent and Sustainable Growth
Commitment to the Location Germany
Investments in New Sites as a Supplement to the Ongoing €1.5 Billion Investment Volume

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), is investing in expanding its production capacities in Germany and the USA. The pharmaceutical service provider will relocate its development services site within the USA and continue to expand there. At the same time, Vetter plans to establish another site in Saarlouis, Saarland, for the commercial production of approved medicines to supply the market, alongside its ongoing capacity expansions in Ravensburg and Langenargen. This responds to the worldwide increasing demand for the manufacturing of injectable medicines.

“Vetter's history is characterized by foresighted, strategic planning that enables us, as an independent family business, to achieve sustainable and dynamic growth,” says Senator h.c. Udo J. Vetter, Chairman of the Supervisory Board and member of the founding family. “With the investments decided upon, we reaffirm our commitment on both continents and also ensure that Vetter remains part of a growing market in the future.”

Vetter Supports Pharma Strategy Germany

An important factor in the company's decision is the increased planning security of a future site in Germany. The extensive experience of the pharmaceutical service provider with large investment projects in Germany allows for more reliable cost and timeline calculations. Furthermore, Vetter can better leverage the existing infrastructure and continue collaborating with existing suppliers. Additionally, the German federal government has emphasized the importance of the industry as a key sector for Germany with the adoption of a national pharma strategy. Vetter itself has over 70 years of success and experience at its locations in the Lake Constance-Oberschwaben region.

The Saarland state government plans to establish a technology park in Saarlouis with the start of Vetter's settlement. Planning for the phased development of the approximately 50-hectare site has already begun. The planned investment amounts to several hundred million euros. Production of injectable medicines on site is scheduled to begin around 2030. The pharmaceutical service provider also plans to create up to 2,000 additional jobs locally in the coming years.

Managing Director Thomas Otto: “Germany, and specifically Saarland, has proven to be the location with the best conditions for expanding our commercial capacities after careful consideration. In addition to the unchanged and growing competencies and capacities at our sites in and around Ravensburg, we can further expand our offerings. We also take responsibility for patients and customers worldwide who rely on our high quality standards.”

Strategic Expansion of the Development Site USA

The positive market development also affects the Vetter site in Skokie, Illinois. Like the company's second clinical manufacturing site in Rankweil, Vorarlberg, it specializes in projects in early clinical development phases. Both locations continue to develop positively and are experiencing increasing demand.

With the planned move of the Skokie site to the land in Des Plaines acquired a few years ago, Vetter is focusing on further expanding its Development Services. New buildings for clinical filling and related services will be constructed on site. The plan is to double the current capacities in Skokie. Additionally, the new site provides space for potential future expansions.

“The decisions of the Advisory Board align with our commitment to meet the long-term capacity needs of our clinical and commercial customers and their patients,” adds Managing Director Peter Sölkner. “We are already implementing extensive investments at our sites in Ravensburg and Langenargen, but market demand for additional capacities remains. We are proud to make further investments in the USA and Germany.”